Gregory P. Chang

12 Patents

• US123848472025

  Cancer Therapy Involving an Anti-pd1 Antibody and a Multi-specific Binding Protein That Binds NKG2D, CD16, and a Tumor-associated Antigen

  Dragonfly Therapeutics, Inc.

  0 cites
• US123848512025

  Multi-specific Binding Proteins That Bind BCMA, NKG2D and CD16, and Methods of Use

  Dragonfly Therapeutics, Inc.

  0 cites
• US123783182025

  Proteins Binding NKG2D, CD16 and a Tumor-associated Antigen

  DRAGONFLY THERAPEUTICS, Inc.

  0 cites
• US122757912025

  Multi-specific Binding Proteins That Bind HER2, NKG2D, and CD16, and Methods of Use

  Dragonfly Therapeutics, Inc.

  0 cites
• US122642002025

  Antibody Variable Domains Targeting the NKG2D Receptor

  Dragonfly Therapeutics, Inc.

  0 cites
• US122151572025

  Multi-specific Binding Proteins That Bind CD33, NKG2D, and CD16, and Methods of Use

  Dragonfly Therapeutics, Inc.

  0 cites
• US121577712024

  Proteins Binding NKG2D, CD16 and CLEC12A

  Dragonfly Therapeutics, Inc.

  0 cites
• US121293002024

  Antibody Variable Domains Targeting the NKG2D Receptor

  Dragonfly Therapeutics, Inc.

  0 cites
• US119393842024

  Antibody Variable Domains Targeting the NKG2D Receptor

  Dragonfly Therapeutics, Inc.

  0 cites
• US118847322024

  Proteins Binding HER2, NKG2D and CD16

  Dragonfly Therapeutics, Inc.

  0 cites
• US118847332024

  Antibody Variable Domains Targeting the NKG2D Receptor

  Dragonfly Therapeutics, Inc.

  0 cites
• US118345062023

  Multi-specific Binding Proteins That Bind NKG2D, CD16, and a Tumor-associated Antigen for Activation of Natural Killer Cells and Therapeutic Uses Thereof to Treat Cancer

  Dragonfly Therapeutics, Inc.

  0 cites